Physician profile
Robert B Vranian
NPI 1083601611
$13,951.29
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,780 · 2020: $4,010 · 2021: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12,494.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $220.12 | 2019-2020 | |
| Astellas Pharma US INC | $194.79 | 2019-2020 | |
| Pfizer INC. | $177.16 | 2019-2021 | |
| Akcea Therapeutics, INC. | $126.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $103.99 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $100.06 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $60.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.53 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $55.65 | 2019-2021 | |
| Nuwellis, INC. | $52.23 | 2019 | |
| Amarin Pharma, INC. | $50.20 | 2019-2020 | |
| United Therapeutics Corporation | $43.59 | 2019-2021 | |
| Allergan, INC. | $28.09 | 2019 | |
| Abbott Laboratories | $26.84 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $20.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.94 | 2019 | |
| Merck Sharp & Dohme LLC | $14.70 | 2021 | |
| Medtronic Vascular, INC. | $14.27 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2019 | |
| Gilead Sciences, INC. | $11.58 | 2019 | |
| Itamar Medical INC | $11.34 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vranian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.